In 2012, Dutch researchers found that a combination of the levels of ER/PgR expression and 70-gene signature (MammaPrintTM, Agendia BV, Amsterdam; cleared by the FDA for risk assessment) was associated with 10-year breast cancer-specific patient survival [34]. The gene discussed is ESR1; the disease is breast carcinoma.